Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Infigratinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bridgebio Advances Achondroplasia Drug On Strong Data
    Bridgebio Advances Achondroplasia Drug On Strong Data

    13 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/highly-impressive-data-propels-bridgebios-achondroplasia-drug-forward

    BIOSPACE
    13 Feb 2026
    Share Share
    Bridgebio To Host Achondroplasia Investor Webinar On January 9Th
    Bridgebio To Host Achondroplasia Investor Webinar On January 9Th

    02 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/02/3212112/0/en/BridgeBio-to-Host-Achondroplasia-Investor-Webinar-on-Friday-January-9th-at-8-00-am-ET.html

    GLOBENEWSWIRE
    02 Jan 2026
    Share Share
    BridgeBio Announce Commercial Progress, Updates, & 2025 Milestones
    BridgeBio Announce Commercial Progress, Updates, & 2025 Milestones

    13 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/13/3008704/0/en/BridgeBio-Announces-Commercial-Progress-Program-Updates-and-2025-Milestones.html

    GLOBENEWSWIRE
    13 Jan 2025
    Share Share
    BridgeBio data show sustained benefit for achondroplasia drug
    BridgeBio data show sustained benefit for achondroplasia drug

    05 Jun 2024

    // Ned Pagliarulo BIOPHARMADIVE

    https://www.biopharmadive.com/news/bridgebio-infigratinib-achondroplasia-propel-study-results/717914/

    Ned Pagliarulo BIOPHARMADIVE
    05 Jun 2024
    Share Share
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study

    04 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/04/2892934/0/en/BridgeBio-Announces-Durable-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-and-First-Participant-Consented-in-ACCEL-for-Hypochondroplasia.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892563/0/en/BridgeBio-to-Host-Call-on-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-on-June-4-2024.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.